ArriVent BioPharma, Inc. Common Stock
NasdaqGM AVBP
ArriVent BioPharma, Inc. Common Stock Share Price on January 14, 2025: USD 24.85
-
ArriVent BioPharma, Inc. Common Stock 52-week high Share Price is USD 35.63 on November 07, 2024, which is 43.38% above the current Share Price.
-
ArriVent BioPharma, Inc. Common Stock 52-week low Share Price is USD 15.30 on April 24, 2024, which is -38.43% below the current Share Price.
-
ArriVent BioPharma, Inc. Common Stock average Share Price for the last 52 weeks is USD 22.68.
| Date | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) |
|---|
| CEO | Dr. Zhengbin Yao Ph.D. |
| IPO Date | Jan. 26, 2024 |
| Location | United States |
| Headquarters | 18 Campus Boulevard |
| Employees | 40 |
| Sector | Health Care |
| Industries | |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email